CR20250205A - Derivados de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopirrolidin-3-il) butan-2-il) benzamida como inhibidores de proteasa para tratar o prevenir la infección por coronavirus. - Google Patents

Derivados de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopirrolidin-3-il) butan-2-il) benzamida como inhibidores de proteasa para tratar o prevenir la infección por coronavirus.

Info

Publication number
CR20250205A
CR20250205A CR20250205A CR20250205A CR20250205A CR 20250205 A CR20250205 A CR 20250205A CR 20250205 A CR20250205 A CR 20250205A CR 20250205 A CR20250205 A CR 20250205A CR 20250205 A CR20250205 A CR 20250205A
Authority
CR
Costa Rica
Prior art keywords
sub
amino
compounds
oxopyrrolidin
butan
Prior art date
Application number
CR20250205A
Other languages
English (en)
Inventor
Valerie W Shurtleff
Craig A Parish
Mayuri Gupta
Franca-Maria Klingler
Jing Su
Christopher Charles Nawrat
Quang T Truong
Mark Eric Layton
Iii John J Acton
Iii Michael J Kelly
John A Mccauley
Lera Ruiz Manuel De
Gregori J Morriello
Anthony J Roecker
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of CR20250205A publication Critical patent/CR20250205A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona un compuesto de Fórmula I en donde R1, R2, R3, R4, R5, R6, R7 y los subíndices x y n son como se describen en el presente 5 documento, y composiciones farmacéuticas que comprenden uno o más de dichos compuestos, y métodos para usar dichos compuestos para el tratamiento, la inhibición o la mejora de una o más patologías que podrían beneficiarse de la inhibición de un coronavirus, incluyendo el SARS-CoV, el MERS-CoV y el SARS-CoV-2. Los compuestos de la presente invención podrían usarse además en combinación con otros agentes terapéuticamente eficaces, incluyendo, pero sin 10 limitación, otros fármacos útiles para el tratamiento de la infección por coronavirus. La invención además se refiere a procesos para preparar compuestos de Fórmula I y composiciones farmacéuticas que comprenden compuestos de Fórmula I y sales farmacéuticamente aceptables de los mismos.
CR20250205A 2022-11-22 2023-11-20 Derivados de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopirrolidin-3-il) butan-2-il) benzamida como inhibidores de proteasa para tratar o prevenir la infección por coronavirus. CR20250205A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263427330P 2022-11-22 2022-11-22
US202363485677P 2023-02-17 2023-02-17
PCT/US2023/080450 WO2024112621A1 (en) 2022-11-22 2023-11-20 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)butan-2-yl)benzamide derivatives as protease inhibitors for treating or preventing coronavirus infection

Publications (1)

Publication Number Publication Date
CR20250205A true CR20250205A (es) 2025-06-25

Family

ID=89452633

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250205A CR20250205A (es) 2022-11-22 2023-11-20 Derivados de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopirrolidin-3-il) butan-2-il) benzamida como inhibidores de proteasa para tratar o prevenir la infección por coronavirus.

Country Status (16)

Country Link
US (1) US20240228535A1 (es)
EP (1) EP4622959A1 (es)
JP (1) JP7744536B2 (es)
KR (1) KR20250109233A (es)
CN (1) CN120603813A (es)
AU (1) AU2023385361A1 (es)
CL (1) CL2025001501A1 (es)
CR (1) CR20250205A (es)
DO (1) DOP2025000116A (es)
GE (1) GEAP202516786A (es)
IL (1) IL320990A (es)
JO (1) JOP20250121A1 (es)
MX (1) MX2025005933A (es)
PE (1) PE20251702A1 (es)
TW (1) TWI911592B (es)
WO (1) WO2024112621A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds
WO2026082104A1 (en) * 2024-10-16 2026-04-23 Yuanyi Wise Tech (Ningbo) Ltd. Silicon-containing compounds as antivirals and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37381A (es) * 2016-08-30 2018-03-23 Glaxosmithkline Ip No 2 Ltd Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
CN115667209A (zh) * 2020-04-23 2023-01-31 普渡研究基金会 用于治疗sars的化合物
EP4635972A3 (en) * 2020-07-20 2025-12-24 Enanta Pharmaceuticals, Inc. Functionalized peptides as antiviral agents
US11866407B2 (en) * 2021-04-20 2024-01-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection

Also Published As

Publication number Publication date
CN120603813A (zh) 2025-09-05
JOP20250121A1 (ar) 2025-05-20
IL320990A (en) 2025-07-01
DOP2025000116A (es) 2025-06-30
MX2025005933A (es) 2025-07-01
EP4622959A1 (en) 2025-10-01
TWI911592B (zh) 2026-01-11
JP2025530610A (ja) 2025-09-17
CL2025001501A1 (es) 2025-09-05
AU2023385361A1 (en) 2025-05-22
US20240228535A1 (en) 2024-07-11
GEAP202516786A (en) 2025-09-25
TW202428253A (zh) 2024-07-16
KR20250109233A (ko) 2025-07-16
WO2024112621A1 (en) 2024-05-30
PE20251702A1 (es) 2025-07-02
JP7744536B2 (ja) 2025-09-25

Similar Documents

Publication Publication Date Title
MX2025005933A (es) Derivados de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopirrolidin-3-il)butan-2-il)benzamida como inhibidores de la proteasa para el tratamiento o la prevencion de la infeccion por coronavirus
MX2023000798A (es) Peptidos funcionalizados como agentes antivirales.
CL2023001476A1 (es) Nuevos agentes antivirales derivados de la espiropirrolidina
MY196455A (en) Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
JOP20220282A1 (ar) مركبات مفيدة لتثبيط كيناز ret
JOP20220227A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
CO2025001287A2 (es) Inhibidores de la proteasa principal de sars-cov2
AR127247A1 (es) Inhibidores de cdk2 de ciclopentilpirazol
MX2024001377A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
CY1111102T1 (el) 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv
MX2023003332A (es) Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades.
MX2023007287A (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas.
MX2025001865A (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr
MX2025013861A (es) Compuestos anti virus de la inmunodeficiencia humana (vih)
BR112022007404A2 (pt) Compostos e composições para o tratamento de doenças parasíticas
CO2025006474A2 (es) Derivados de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopirrolidin-3-il)butan-2-il)benzamida como inhibidores de proteasa para tratar o prevenir la infección por coronavirus
MX2023015246A (es) Compuestos pirimidinicos para usar como inhibidores de map4k1.
ZA202510255B (en) Crystal forms of sodium salt of polycyclic carbamoylpyridone derivative, and preparation method therefor and use thereof
UY39862A (es) Nuevos agentes antivirales derivados de espiropirrolidina
AR122363A1 (es) Una composición farmacéutica que comprende derivados de ftalazinona
CA3273045A1 (en) 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)butan-2-yl)benzamide derivatives as protease inhibitors for treating or preventing coronavirus infection
AR126482A1 (es) Agentes antivirales derivados de espiropirrolidina